Detailed narrative
The guide-down: a rare miss for a company built on beating its numbers
Boston Scientific reduced full-year 2026 organic guidance to 6.5%-8% (from prior above-market framing) and guided Q2 to 5%-7%, a decision Mike Mahoney repeatedly said the company 'does not take lightly.' Three areas drove the takedown: EP, WATCHMAN and Urology. Management stressed the FY26 guide places BSX at or below its ~8% WAMGR — 'This is not Boston Scientific, it's not what we do' — while reaffirming conviction in the LRP margin (+150 bps) and double-digit EPS commitments.
Mahoney flagged 2027 and 2028 as far easier comp years with a rich launch cadence, calling himself 'very bullish' on them.
WATCHMAN — concomitant strengthening, stand-alone softening
WATCHMAN grew 19% organically but below expectations, with volumes turning down for the first time in early-to-mid February. Management attributes it to annualization of the initial concomitant adoption tailwind plus softening stand-alone cases from hospital-capacity procedure prioritization and evolving reimbursement dynamics (a reimbursement cut has pushed some volume from interventional cardiologists toward EP physicians).
CHAMPION met all primary and secondary endpoints and will support a label update, guideline changes and eventually an updated NCD, but Ken Stein cautioned it 'just takes time' to disseminate data. BSX is adding dedicated WATCHMAN commercial and marketing investment.
Concomitant is ~25% of procedures today, targeted to reach 50% over the LRP; ~50% of US AFib ablations are in high-stroke-risk (CHADS ≥3) candidates.
Electrophysiology — leadership intact but more share erosion assumed
EP grew 22% organically (US +18%, international +30%), with FARAPOINT (PFA focal catheter) performing ahead of expectations and now in full launch, and expanding OPAL/FARAVIEW mapping footprint. Yet BSX cut global EP FY guidance to ~10% (US mid-single-digit implying roughly flat US EP 2Q-4Q, international +20%), assuming greater PFA share erosion than previously modeled amid three large competitors — Medtronic ('solid'), J&J ('enhancing their footprint') and Abbott ('early stages of launch in the US').
Management remains 'highly confident' of retaining PFA leadership in the US and globally through 2026 and the LRP, pointing to a three-launch pipeline: third-generation FARAPULSE and FARAWAVE Ultra (H1 2027) and FANAFLEX (2028).
Urology — commercial disruption in sacral neuromodulation, Stone gaps
Urology grew just 1% organically, dragged by Stone management (China VBP plus core product gaps) and sacral neuromodulation. The Pelvic Health/sacral neuromod business has suffered lingering commercial turnover across region managers, clinical and territory reps; BSX has now refilled leadership and hired/trained nearly 100 new reps, and closed Valencia Technologies (Ecoin Tibial Nerve stim) in April.
Recent FDA approval of a new ureteroscope is expected to unlock the StoneSmart ecosystem alongside LithoVue Elite, with more launches (including an ureteroscope) later in 2026. FY Urology guided to low-to-mid single digits — a below-market year, with a target to approach market growth in 2027.
Q1 financials and the margin architecture
Consolidated revenue was $5.203B, up 11.6% reported (220 bps / $104M FX tailwind), 9.4% operational and organic. Adjusted EPS $0.80 (+6%, high end of guide, ~$0.01 FX headwind🌐). Adjusted gross margin 70.5% fell 100 bps YoY on tariffs and POLARx inventory charges, and FY gross margin is now expected slightly below 2025 on weaker mix.
Adjusted operating margin was 28.8% (GAAP 21.2%); adjusted tax rate 11.7% (stock-comp benefit); adjusted interest/other expense $112M. With less mix benefit, management is defending margin/EPS through restrictive spend controls, shared-services scaling, org optimization and AI-automation initiatives, and R&D reprioritization toward highest-impact programs.
Capital allocation — buyback restart and M&A
Free cash flow was $170M in Q1 ($348M operating cash flow less $177M net capex); FY FCF guided to ~$4B. Cash on hand was $1.453B and gross debt leverage 1.8x as of March 31. The Board added $4B to the buyback (total authorization $5B); with the company restricted until the Penumbra shareholder vote (May 6), BSX intends to repurchase ~$2B in Q2, funded from cash on hand.
Top capital-allocation priority remains strategic tuck-in M&A (Valencia closed; Penumbra pending, expected to close H2 2026), followed by share repurchase.
The 70%+ non-EP/WATCHMAN business — ICVT, Interventional Oncology and Penumbra
Mahoney directed attention to the rest of the portfolio: Interventional Cardiology Vascular Therapies (ICVT +8% organic; IC +9%) is driving double-digit China growth despite VBP, with Agent DCB and imaging exceeding internal expectations; Vascular Therapies grew 7% (double-digit TCAR). Interventional Oncology grew 15%.
Management is building seismic peripheral IVL manufacturing supply ahead of a meaningful 2027 launch across coronary, above- and below-the-knee. Penumbra — with a differentiated thrombectomy portfolio — is expected to become a distinct business unit and, Mahoney said, a 'very unique, powerful growth driver' over the LRP.